| |
| Issue |
Title |
| |
| No 4S (2020): PharmaCOVID |
Rationale for use mefloquine for COVID-19 treatment |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of favipiravir in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice |
Abstract
PDF (Rus)
|
|
Yu. Yu. Kiselev, A. V. Matveev, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Could canakinumab be used for COVID-19? |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Use of unlicensed drugs and off-label drug use: focus on COVID-19 |
Abstract
PDF (Rus)
|
|
S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko |
| |
| No 4S (2020): PharmaCOVID |
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Possibilities for the use of anakinra in COVID-19 |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, A. V. Matveev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge |
Abstract
PDF (Rus)
|
|
A. V. Krykov, V. A. Otdelenov, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Rationality of routine clinical use of olokizumab in COVID-19 |
Abstract
PDF (Rus)
|
|
V. M. Tsvetov, A. V. Matveev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of colchicine in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of umifenovir in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, A. V. Krykov, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of vitamin D3 in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
I. N. Sychev, A. V. Matveev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention |
Abstract
PDF (Rus)
|
|
K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of dipyridamole in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Dexamethasone use in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of remdesivir in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Possibilities for the use of tofacitinib in patients with COVID-19 |
Abstract
PDF (Rus)
|
|
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
Abstract
PDF (Rus)
|
|
V. M. Tsvetov, I. N. Sychev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed? |
Abstract
PDF (Rus)
|
|
Yu. Yu. Kiselev, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy |
Abstract
PDF (Rus)
|
|
V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 |
Abstract
PDF (Rus)
|
|
K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» |
Abstract
PDF (Rus)
|
|
V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev |
| |
| No 4S (2020): PharmaCOVID |
Is it possible to use riamilovir to prevent infection and treat COVID-19? |
Abstract
PDF (Rus)
|
|
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| |
| 1 - 24 of 31 Items |
1 2 > >>
|
